Intervacc AB (SE:IVACC)

:IVACC

IVACC

Intervacc AB

RESEARCH TOOLSreports

Want to see SE:IVACC full AI Analyst Report?

Intervacc AB (IVACC) Price & Analysis

0 Followers

IVACC Stock Chart & Stats

kr0.92

-kr0.06(-5.24%)

At close: Mar 06 4:00 PM EST

kr0.92

-kr0.06(-5.24%)

Day’s Range― - ―

52-Week Rangekr0.57 - kr1.35

Previous CloseN/A

Volume791.15K

Average Volume (3M)373.34K

Market Cap

kr391.94M

Enterprise Valuekr231.05M

Total Cash (Recent Filing)kr160.89M

Total Debt (Recent Filing)kr0.00

Price to Earnings (P/E)―

Beta0.54

Next Earnings

May 13, 2026

EPS Estimate

-0.06

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.10

Shares Outstanding340,813,200

10 Day Avg. Volume453,808

30 Day Avg. Volume373,337

Financial Highlights & Ratios

PEG Ratio0.05

Price to Book (P/B)1.00

Price to Sales (P/S)13.68

P/FCF Ratio-4.11

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)-0.23

Revenue Forecast (FY)kr51.00M

Bulls Say, Bears Say

Bulls Say

Low Leverage / Strong Balance SheetNear-zero debt materially reduces financial risk and interest burden, giving Intervacc durable financial flexibility. Over the next 2–6 months this supports continued R&D and commercialization activities without immediate refinancing pressure, and preserves optionality for partnerships or targeted funding.

Commercial Product / Clear Revenue ModelOwning and commercializing Strangvac provides a tangible, product-driven revenue stream via distribution partners. A marketed veterinary vaccine creates recurring addressable demand, established go-to-market channels, and potential for geographic rollout or licensing, which supports medium-term commercial scalability.

Strong Historical Revenue GrowthHigh historical revenue growth signals meaningful commercial traction for the company’s products and market adoption. If sustained or combined with broader market rollout, this growth provides a foundation for margin recovery and operational leverage as sales scale over the next several months to a year.

Bears Say

Persistent Losses / Gross Loss In 2025A gross loss in 2025 despite rising revenue points to structural cost or product-economics issues. Persistent negative margins undermine sustainable profitability, risk further equity erosion, and require corrective measures to restore unit economics before the business can reliably self-fund growth.

Weak Cash GenerationConsistent negative operating and free cash flow indicates ongoing cash burn and reliance on external funding. Over the medium term this restricts strategic flexibility, increases dilution or financing risk, and can slow commercialization or manufacturing scale-up if additional capital is not secured on reasonable terms.

Volatile Revenue / Uneven Commercial TractionRevenue volatility reflects uneven market adoption and execution risk across regions or partner channels. For a vaccine-focused company dependent on one commercial product, this makes forecasting, supply planning, and margin improvement harder, raising structural uncertainty about sustainable growth and cash flow predictability.

IVACC FAQ

What was Intervacc AB’s price range in the past 12 months?

Intervacc AB lowest stock price was kr0.57 and its highest was kr1.35 in the past 12 months.

What is Intervacc AB’s market cap?

Intervacc AB’s market cap is kr391.94M.

When is Intervacc AB’s upcoming earnings report date?

Intervacc AB’s upcoming earnings report date is May 13, 2026 which is in 12 days.

How were Intervacc AB’s earnings last quarter?

Intervacc AB released its earnings results on Feb 17, 2026. The company reported -kr0.1 earnings per share for the quarter, missing the consensus estimate of -kr0.06 by -kr0.04.

Is Intervacc AB overvalued?

According to Wall Street analysts Intervacc AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Intervacc AB pay dividends?

Intervacc AB does not currently pay dividends.

What is Intervacc AB’s EPS estimate?

Intervacc AB’s EPS estimate is -0.06.

How many shares outstanding does Intervacc AB have?

Intervacc AB has 340,813,200 shares outstanding.

What happened to Intervacc AB’s price movement after its last earnings report?

Intervacc AB reported an EPS of -kr0.1 in its last earnings report, missing expectations of -kr0.06. Following the earnings report the stock price went down -16.471%.

Which hedge fund is a major shareholder of Intervacc AB?

Currently, no hedge funds are holding shares in SE:IVACC

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Intervacc AB

Intervacc AB (publ), a biotechnology company, engages in the research and development of vaccines for bacterial infections in animal health care. The company devlops vaccines for horses, piglets, and dairy cows. It offers Strangvac, a vaccine for equine strangles. The company also markets and sells veterinary medicines; and provides diagnostic services in veterinary bacteriology for veterinary clinics and stud farms. In addition, it is developing vaccines against streptococcus suis and staphylococcus aureus-infections. It serves customers in Nordic countries and the Baltic states. The company is based in Hägersten, Sweden.